Ocugen to Participate in Upcoming Scientific Conferences
Globe Newswire•30/09/2026•07:02 ET
0
Key Highlights
- ➤Ocugen (OCGN) to present modifier gene therapy platform at scientific conferences
- ➤OCU410 Phase 2 ArMaDa trial: twelve-month topline safety and efficacy results presented
- ➤OCU410ST Phase 1 dose-escalation trial results in Stargardt disease presented
- ➤OCU400 three-year safety and efficacy results in retinitis pigmentosa presented
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences.
Euretina Innovation Spotlight (EIS) 2026 Location: VIECON, Vienna, Austria Date: Wednesday, September 30, 2026 Time: 2:34 p.m. CEST Format: Company presentation Title: Ocugen Company Overview Presenter: Abhi Gupta, Executive Vice President, Commercial and Business Development, Ocugen
Get started
Create a free account to read the full story.